NCT05814354View on ClinicalTrials.gov

SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial

PHASE3RecruitingINTERVENTIONAL
Enrollment

530

Participants

Timeline

Start Date

June 30, 2023

Primary Completion Date

January 30, 2025

Study Completion Date

June 30, 2026

Conditions
Breast Cancer
Interventions
DRUG

SHR-A1811

SHR-A1811 is a lyophilized powder for injection intravenously. Administered according to label, as one option for Physician's Choice.

DRUG

Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel

Administered according to label, as one option for Physician's Choice (determined before randomization).

Trial Locations (1)

100021

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY